Klona Biotech is redefining reconstructive medicine with 3D-printed, personalized implants for mechanically demanding tissues like ligaments, tendons, and cartilage. Millions of patients each year require grafts for these tissues, yet donor shortages and graft failure remain major barriers to recovery.

Klona’s proprietary bioprinting platform integrates fiber-reinforced “gel-textile” composites – materials up to twenty times stronger than standard bioprints while remaining compatible with living cells. The result is regenerative implants that combine biological function with real mechanical strength.

Founded by Dylan Yeo (University of Oxford) and Thomas Groom (Imperial College London), Klona is developing its first ligament implant and next-generation printer system to enable hospitals to bioprint patient-specific tissues on demand.